'A turning point for the field': 4 years after Seres failure, Finch posts positive microbiome data
In 2016, one of the first microbiome biotechs failed a major trial, cratering their stock price and casting a years-long pallor on the field. Now, for the second time in as many months, a microbiome company has reported positive, pivotal data.
In a Phase II trial of 206 patients with recurrent C. diff infection — a colon-damaging bacteria that often comes back and can occasionally be fatal — those who were given Finch Therapeutics’ microbiome capsule plus antibiotics had a 74.5% chance of going 8 weeks without a repeat infection. That compared to 61.5% for a control arm that received antibiotics alone.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.